Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:48:06 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Advanced Proteome Therapeutics Corp (2)
Symbol APC
Shares Issued 41,127,080
Close 2023-12-04 C$ 0.005
Market Cap C$ 205,635
Recent Sedar+ Documents

Advanced Proteome heads to CTO jail for not filing

2023-12-06 17:30 ET - News Release

Subject: Advanced Proteome Therapeutics Corp. - News Release PDF Document File: Attachment CTO & Trade Suspension December 6 2023.pdf ADVANCED PROTEOME THERAPEUTICS ANNOUNCES CEASE TRADE ORDER & SUSPENSION OF TRADING FROM THE NEX Vancouver, British Columbia / November 21, 2022 Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSXV: APC) (FSE: 0E8), announces that it received a cease trade order ("CTO"), on December 5th, 2023 from the British Columbia Securities Commission ("BCSC") as a result of the Company's failure to file its audited annual financial statements and corresponding management's discussion and analysis for the year ended July 31, 2023, including the CEO and CFO certifications. The order will remain in effect until the Company files its Financial Documents. Further, on December 6th, the TSX Venture Exchange (the "TSXV") suspended trading in the Company's securities on the NEX Exchange as a result of said CTO. Upon completion of the Filings and revocation of the CTO by the BCSC, the Company will submit the required materials to the TSXV requesting the reinstatement of trading. Revocation of the CTO and reinstatement of trading are expected to occur within a few days after the Filings are made. FOR FURTHER INFORMATION PLEASE CONTACT: Advanced Proteome Therapeutics Corporation Paul Woodward President and CEO Tel: 604 690-3797 http://www.advancedpc.ca Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "intends", "anticipates", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulators. Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward- looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

© 2026 Canjex Publishing Ltd. All rights reserved.